Directors of clinical trial innovation, business development, clinical operations, clinical research and therapeutic heads are the main profiles of attendees at the past DPharm event. Meet these professionals and other potential clients in the clinical trial field for your LSP when you attend this conference that is set for February 8 and 9, 2017 at the Millennium Hotel in London. Continue reading
Pitch your translation services to senior clinical supply chain professionals who will be in attendance at the Clinical Trial Supply Europe. The speaker list for this event include representatives from Abbvie, Parexel, Boehringer Ingelheim, and Teva. Continue reading
The EU is expected to enact a sweeping overhaul of its regulatory framework for medical devices in early 2017, which includes changes to requirements for multilingual documentation. Brexit also adds to uncertainty. Continue reading
Two barriers to entry face US medical device companies that want in to China, and the Chinese government has begun to close loopholes; a look at opportunities and expert insights on the medical device market in the world’s most populous nation. Continue reading
Since the start of 2015, China has launched 22 new policies aimed at reforming the regulatory framework for local and international pharma and medical device companies. Sponsored by Lionbridge, Slator’s Shanghai roundtable provided participants a timely update on how policy impacts day-to-day operations Continue reading
Medical device manufacturers need to keep tight control over content to comply with regulators while staying nimble to get their message across to customers: an exclusive look behind the scenes at how translation is managed at MED-EL, an Austrian manufacturer of hearing implants. Continue reading
Clinical trials are on the rise in Russia, with a 13% increase in the third quarter of 2015. LSPs active in life sciences would do well to keep watch. Continue reading
As CROs are increasingly relying on ePRO in clinical trials, the demand for translation and localization of ePRO systems may likewise increase. Continue reading
This information will never be shared with third parties. No Spam.